REPLIMUNE GROUP INC's ticker is REPL and the CUSIP is 76029N106. A total of 99 filers reported holding REPLIMUNE GROUP INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,760 | -13.5% | 2,616 | +17.4% | 0.00% | -33.3% |
| Q2 2023 | $51,757 | +15.9% | 2,229 | -11.8% | 0.00% | +50.0% |
| Q1 2023 | $44,644 | -33.1% | 2,528 | +3.1% | 0.00% | -33.3% |
| Q4 2022 | $66,694 | +57.5% | 2,452 | 0.0% | 0.00% | +50.0% |
| Q3 2022 | $42,346 | +39.4% | 2,452 | +41.1% | 0.00% | +100.0% |
| Q2 2022 | $30,380 | +2.9% | 1,738 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $29,511 | -84.6% | 1,738 | -75.5% | 0.00% | -66.7% |
| Q4 2021 | $191,922 | -8.6% | 7,082 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $209,910 | -22.9% | 7,082 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $272,090 | +32.6% | 7,082 | +5.3% | 0.00% | +33.3% |
| Q1 2021 | $205,180 | -20.0% | 6,725 | 0.0% | 0.00% | -25.0% |
| Q4 2020 | $256,559 | +65.7% | 6,725 | 0.0% | 0.00% | +33.3% |
| Q3 2020 | $154,810 | -2.0% | 6,725 | +5.8% | 0.00% | 0.0% |
| Q2 2020 | $158,021 | – | 6,359 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 3,050,187 | $53,866,302 | 35.13% |
| Atlas Venture Life Science Advisors, LLC | 2,098,300 | $37,055,978 | 5.02% |
| Redmile Group, LLC | 3,811,988 | $67,319,708 | 2.92% |
| Nan Fung Group Holdings Ltd | 189,339 | $3,343,727 | 2.28% |
| Altium Capital Management LP | 148,000 | $2,613,680 | 1.45% |
| Integral Health Asset Management, LLC | 395,000 | $6,975,700 | 1.40% |
| BVF INC/IL | 2,143,036 | $37,846,016 | 1.38% |
| Resolute Capital Asset Partners LLC | 82,500 | $1,457 | 1.06% |
| SECTORAL ASSET MANAGEMENT INC | 262,200 | $4,630,452 | 0.89% |
| Frazier Life Sciences Management, L.P. | 686,762 | $12,128,217 | 0.88% |